Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2023 to Q4 2025

Type / Class
Equity / Ordinary Shares, $0.000000005 par value
Symbol
AKTX on Nasdaq
Shares outstanding
94,284,567,045
Price per share
$0.24
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
4,452,856
Total reported value
$1,286,473
% of total 13F portfolios
0%
Share change
+3,192,966
Value change
+$872,091
Number of holders
21
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Huh Hoyoung 18% +18% $4,367,927,440 +$2,377,245,520 18,199,697,667 +119% Hoyoung Huh, M.D., Ph.D. 02 Mar 2026
Patel Samir Rashmikant 10% $2,334,051,600 9,725,215,000 Samir R. Patel 02 Mar 2026
Prudo-Chlebosz Raymond 8.9% -4.4% $2,013,918,352 +$831,534,160 8,391,326,467 +70% Ray Prudo, M.D. 02 Mar 2026

As of 31 Dec 2025, 21 institutional investors reported holding 4,452,856 shares of Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX). This represents 0% of the company’s total 94,284,567,045 outstanding shares.

Institutional Holders of Akari Therapeutics Plc - Ordinary Shares, $0.000000005 par value (AKTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 4,452,856 $1,286,473 +$872,091 $0.29 21
2025 Q3 1,170,067 $1,181,319 +$593,371 $1.01 16
2025 Q2 550,740 $644,311 +$288,311 $1.17 15
2025 Q1 304,298 $377,330 -$22,653 $1.24 10
2024 Q4 322,783 $393,794 +$114,040 $1.22 14
2024 Q3 181,321 $535,895 +$11,085 $2.95 10
2024 Q2 180,188 $488,063 +$56,787 $2.70 10
2024 Q1 174,742 $326,347 +$98,948 $1.86 8
2023 Q4 121,755 $379,836 -$22,758 $3.12 7
2023 Q3 123,042 $486,015 +$486,015 $3.95 7